An official website of the United States government
Home
| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9289 | Nivolumab and hyaluronidase-nvhy | OPDIVO QVANTIG | 2mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2025 | Jul 9, 2025 | In Use | ||
| J9341 | Thiotepa (tepylute) | Tepylute | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2025 | Jul 9, 2025 | In Use | ||
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| J1326 | Zolbetuximab-clzb | Vyloy | 2mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Jul 9, 2025 | In Use | ||
| C9174 | Datopotamab Deruxtecan | Datroway | 1mg | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I | No | 2025 | Jul 9, 2025 | Sep 8, 2025 | In Use | |
| J9382 | Zenocutuzumab-zbco | Bizengri | 1mg | Immunotherapy | Bispecific Antibody | HER2, HER3 | No | 2024 | Jul 9, 2025 | In Use | ||
| J9174 | Docetaxel (beizray) | Beizray | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2024 | Jul 9, 2025 | In Use | ||
| C9175 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Jul 9, 2025 | Sep 8, 2025 | In Use | |
| Q2058 | Obecabtagene autoleucel | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Jul 9, 2025 | In Use | ||
| J9072 | Cyclophosphamide (frindovyx) | Frindovyx | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2025 | Sep 8, 2025 | In Use | ||
| Q5159 | Denosumab-dssb | Ospomyv, Xbryk | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| Q5158 | Denosumab-bnht | Bomyntra, Conexxence | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| C9306 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | Sep 8, 2025 | In Use | ||
| J0614 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Sep 8, 2025 | In Use | ||
| J9011 | Datopotamab Deruxtecan | Datroway | 1mg | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I, TROP2 | No | 2025 | Sep 8, 2025 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
